Paul McGarty, chief
David Klaum, senior
Fougera's (Melville, NY) philosophy "Make No Compromises" is behind everything the company does. The company is the leader in the development, manufacture, and commercialization of multisource dermatology products in the United States. Fougera's more than 600 employees work at its 2 facilities in New York, as well as facilities in Pennsylvania and Arizona. Throughout its 160-year history, Fougera has strived to deliver innovative quality pharmaceuticals, reliable customer service, and total product value for its customers.
Fougera dates back to 1849 when Edmond Fougera, a pharmacist from Chaillon, France, opened a small drugstore in Brooklyn, New York. In the 1930s and 1940s, E. Fougera and Company prospered by importing products and forming joint ventures. Its entrance into the evolving generic market came in 1966, setting the stage for the evolution of the company into the topical generic leader it is known for today. During the 1970s, Fougera created a unique position for itself with the generic market by introducing high-quality products packaged in a uniform yellow and white color design.
Fougera stands apart from other generic companies because of its superior quality of products, dedicated sales and customer service teams, a rich pipeline of innovative product developments, and unequal company heritage and leadership. The company, which currently manufactures approximately 250 SKUs, continues to set the pace by introducing new products and setting goals to introduce between 8 and 12 products each year.
Fougera's commitment goes beyond FDA approvals. Since 1991, the company has partnered with the international relief organization AmeriCares and recently created a flagship program. Working under the theme "Produce to Give," Fougera provides the medicines that have been specifically identified and requested as most needed due to war, poverty, or natural disasters around the world. "Fougera's efforts are a stellar example of corporate social responsibility and the benefit of partnerships between businesses and nonprofit organizations," said the relief organization.
The focus on reforming the nation's health care system, combined with the growth of hospital, retail, and managed care buying groups, have served to increase the demand for more efficient overall operational policies. Fougera's systems and processes are evaluated and updated continually in order to manufacture the highest quality products possible. Its state-of-the-art technology allows a more precise view of its products at all phases of the manufacturing process. This investment is paramount to ensure that every Fougera product on the market continues to deliver on the company's core philosophy of Make No Compromises.
In terms of goals for 2008 and beyond, Fougera and its parent company, Nycomed US Inc, have demonstrated their dedication to becoming a top dermatology company that will leverage their core competencies in topical products and expand their development efforts from pure generics to selective new therapies in dermatology. Fougera is determined to maintain its leadership position.
For more information, visit Fougera's Web site at www.fougera.com, or call 800-645-9833.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs